Aris Theologis

Prior to joining Initiate, Aris was part of the founding team and Chief Business Officer at Evozyne, Inc., a leader in generative AI for biology, where he led several functional areas within the business, including business development, commercial strategy, finance, marketing, talent, and legal. Aris was instrumental in securing numerous strategic partnerships with Takeda Pharmaceuticals (TAK) and NVIDIA (NVDA) and helped the company raise more than $100M in capital from leading investors.

Prior to Evozyne, Aris was Vice President of Portfolio Management at Paragon Biosciences, a global life science leader that creates, builds and funds innovative biology-based companies. Aris led the incubation and strategic financing of numerous portfolio companies over a two year period specifically focused on bio-pharmaceuticals.

Before joining Paragon Biosciences, Aris was on the commercial, business development, and strategy teams at Castlight Health (IPO: CSLT), a leading healthcare cost & quality transparency tool for self-funded employers. Aris helped to secure more than 40 strategic partnerships with national health plans (UnitedHealth Group, CVS, Cigna), pharmacy benefit managers (Express Scripts, OptumRx), and dental and behavioral health providers.

Prior to Castlight Health, Aris was on the commercial team at Crescendo Biosciences, a pioneer in molecular diagnostics, specifically focused on immunology. Aris joined the company as employee number 5 and helped to grow the business as it was ultimately sold to Myriad Genetics (Aq: MYGN). Also prior to Castlight Health, Aris was an Amil-Harvard fellow in Brazil. At Amil, Aris worked on corporate strategy and new product development up until Amil was sold for $4.9B to UnitedHealth Group (Aq: UNH) in 2012.

Aris earned his MBA from Harvard Business School and received his bachelor’s degree in biochemistry and biophysics (with honors) from Stanford University.